Skip to main
CTSO
CTSO logo

CytoSorbents (CTSO) Stock Forecast & Price Target

CytoSorbents (CTSO) Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 60%
Buy 30%
Hold 10%
Sell 0%
Strong Sell 0%

Bulls say

CytoSorbents Corp has demonstrated strong revenue growth, with estimated revenues reaching $9.2 million in Q4 2023, reflecting a significant increase from the previous quarter's $7.35 million. The company anticipates a total revenue growth of 1.5%-2.5% year-over-year, along with full-year growth projected at approximately 14%, indicating continued market adoption and expansion. Furthermore, a gross margin rebound to approximately 70% showcases improved operational efficiency, bolstering the company's financial health and sustaining a positive outlook.

Bears say

CytoSorbents Corp is facing challenges related to gross margin pressure, which could hinder profitability despite an improved topline revenue outlook. The company operates in a volatile environment that includes risks such as fluctuating commodity costs, rising interest rates, and weakened consumer confidence, which may adversely impact its sales performance. Furthermore, consensus estimates for future earnings per share (EPS) reflect a cautious sentiment, with expectations remaining stagnant and indicating potential difficulties in achieving growth.

CytoSorbents (CTSO) has been analyzed by 10 analysts, with a consensus rating of Buy. 60% of analysts recommend a Strong Buy, 30% recommend Buy, 10% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of CytoSorbents and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About CytoSorbents (CTSO) Forecast

Analysts have given CytoSorbents (CTSO) a Buy based on their latest research and market trends.

According to 10 analysts, CytoSorbents (CTSO) has a Buy consensus rating as of Jun 21, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $11.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $11.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

CytoSorbents (CTSO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.